Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2DiabetesHealthy
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 84
- Registration Number
- NCT02479022
Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT02470039
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 706
- Registration Number
- NCT02461589
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Truro, United Kingdom
A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 335
- Registration Number
- NCT02453685
- Locations
- 🇦🇪
Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
Phase 2
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 957
- Registration Number
- NCT02453711
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Rotherham, United Kingdom
A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 308
- Registration Number
- NCT02443155
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 506
- Registration Number
- NCT02420262
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1262
- Registration Number
- NCT02392117
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency
Phase 3
Completed
- Conditions
- Growth Hormone DisorderAdult Growth Hormone Deficiency
- Interventions
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 92
- Registration Number
- NCT02382939
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
Changing Diabetes in Children
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3089
- Registration Number
- NCT02382757
© Copyright 2025. All Rights Reserved by MedPath